Obesity kings’ buffet is slimmer than it looks
Eli Lilly and Novo Nordisk dominate the weight-loss market. Yet Pfizer, Roche and others are scooping up new drugs in a bid to grab a slice of a $130 billion revenue opportunity. The potential to improve on current treatments means today’s leaders will have to share the feast.
